Search

Displaying results 311 - 320 of 332 in total
  1. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  2. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.

  3. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [L18438] Remdesivir was also approved by the European Commission on July 3, 2020.

  4. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier … The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization.

  5. Indication

    Severe Pain

    go.drugbank.com/conditions/DBCOND0066540
    Drugs: Acetaminophen · Acetylsalicylic acid · Buprenorphine · Butorphanol · Cannabidiol · Codeine +23 more
  6. Drug

    Multipotent adult arogenitor cells

    go.drugbank.com/drugs/DB15742
    Investigational

    MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hemato...

  7. Drug

    Umbilical Cord Blood Hematopoietic Stem Cells

    go.drugbank.com/drugs/DB15723
    Investigational

    Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels

  8. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.

  9. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by...

  10. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth f...